AKESO INC. O.N. Market Cap ($9.89 Billion)
Market Cap & Net Worth: AKESO INC. O.N. (4RY)
AKESO INC. O.N. market cap. AKESO INC. O.N. (F:4RY) has a market capitalization of $9.89 Billion (€8.46 Billion) as of November 1, 2026. Listed on the F stock exchange, this Germany-based company holds position #2184 globally and #465 in its home market, demonstrating a -12.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AKESO INC. O.N.'s stock price €9.19 by its total outstanding shares 921143176 (921.14 Million). Also see how efficiently does AKESO INC. O.N. generate cash for how efficiently the company converts equity into cash flow.
AKESO INC. O.N. Market Cap History (2020–2026)
AKESO INC. O.N. market cap history from 2020 to 2026. Data shows growth from $4.09 Billion to $9.89 Billion (18.88% CAGR). Check current stock price of AKESO INC. O.N. for real-time trading data and today's change.
AKESO INC. O.N. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AKESO INC. O.N.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is AKESO INC. O.N. growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.23x
AKESO INC. O.N.'s market cap is 4.23 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $3.75 Billion | $225.63 Million | -$1.07 Billion | 16.61x | N/A |
| 2022 | $5.34 Billion | $837.66 Million | -$1.17 Billion | 6.38x | N/A |
| 2023 | $5.76 Billion | $4.53 Billion | $2.03 Billion | 1.27x | 2.84x |
| 2024 | $7.70 Billion | $2.12 Billion | -$514.51 Million | 3.63x | N/A |
| 2025 | $12.92 Billion | $3.06 Billion | -$1.11 Billion | 4.23x | N/A |
Competitor Companies of 4RY by Market Capitalization
Companies near AKESO INC. O.N. in the global market cap rankings as of November 1, 2026. Also see AKESO INC. O.N. asset portfolio for a full breakdown of the balance sheet.
Key companies related to AKESO INC. O.N. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of AKESO INC. O.N. (2020–2026)
Market capitalization of AKESO INC. O.N. from 2020 to today. Between 2020 and today, AKESO INC. O.N.'s market cap moved from $4.09 Billion to $ 9.89 Billion, with a yearly change of 18.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €9.89 Billion | -23.43% |
| 2025 | €12.92 Billion | +67.83% |
| 2024 | €7.70 Billion | +33.64% |
| 2023 | €5.76 Billion | +7.86% |
| 2022 | €5.34 Billion | +42.53% |
| 2021 | €3.75 Billion | -8.42% |
| 2020 | €4.09 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of AKESO INC. O.N. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.89 Billion USD |
| MoneyControl | $9.89 Billion USD |
| MarketWatch | $9.89 Billion USD |
| marketcap.company | $9.89 Billion USD |
| Reuters | $9.89 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About AKESO INC. O.N.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell car… Read more